Abe S - Search Results

1

Impact of Interferon-Free Direct-Acting Antivirals on the Incidence of Extrahepatic Malignancies in Patients with Chronic Hepatitis C.

Honma Y, Shibata M, Morino K, Koya Y, Hayashi T, Ogino N, Kusanaga M, Oe S, Miyagawa K, Abe S, Tabaru A, Harada M. Honma Y, et al. Among authors: abe s. Dig Dis Sci. 2023 Feb;68(2):685-698. doi: 10.1007/s10620-022-07686-3. Epub 2022 Sep 14. Dig Dis Sci. 2023. PMID: 36100828

2

Biliary obstruction caused by intrabiliary transplantation from hepatocellular carcinoma.

Narita R, Oto T, Mimura Y, Ono M, Abe S, Tabaru A, Yoshikawa I, Tanimoto A, Otsuki M. Narita R, et al. Among authors: abe s. J Gastroenterol. 2002 Jan;37(1):55-8. doi: 10.1007/s535-002-8134-0. J Gastroenterol. 2002. PMID: 11824802

3

High-dose interferon-alpha therapy lowers the levels of serum fibrogenesis markers over 5 years in chronic hepatitis C.

Abe S, Tabaru A, Ono M, Tai M, Narita R, Moriyama A, Otsuki M. Abe S, et al. Hepatol Res. 2003 Jan;25(1):22-31. doi: 10.1016/s1386-6346(02)00203-6. Hepatol Res. 2003. PMID: 12644035

4

Early decrease in serum IV-7S levels during IFN treatment predicts anti-fibrogenic effect in nonresponders with chronic hepatitis C.

Abe S, Narita R, Hiura M, Jia DM, Tabaru A, Otsuki M. Abe S, et al. J Gastroenterol. 2004;39(3):247-54. doi: 10.1007/s00535-003-1286-5. J Gastroenterol. 2004. PMID: 15065002

5

Insulin resistance and insulin secretion in chronic hepatitis C virus infection.

Narita R, Abe S, Kihara Y, Akiyama T, Tabaru A, Otsuki M. Narita R, et al. Among authors: abe s. J Hepatol. 2004 Jul;41(1):132-8. doi: 10.1016/j.jhep.2004.03.020. J Hepatol. 2004. PMID: 15246219

6

Efficacy of short-term interferon therapy for patients infected with hepatitis C virus genotype 2a.

Tabaru A, Narita R, Hiura M, Abe S, Otsuki M. Tabaru A, et al. Among authors: abe s. Am J Gastroenterol. 2005 Apr;100(4):862-7. doi: 10.1111/j.1572-0241.2005.40826.x. Am J Gastroenterol. 2005. PMID: 15784033 Clinical Trial.

7

Effect of combination therapy with ribavirin and high-dose interferon-alpha2b for 24 weeks in chronic hepatitis C.

Abe S, Narita R, Oto T, Tabaru A, Otsuki M. Abe S, et al. J Gastroenterol Hepatol. 2006 Jan;21(1 Pt 2):308-12. doi: 10.1111/j.1440-1746.2006.04173.x. J Gastroenterol Hepatol. 2006. PMID: 16460492 Clinical Trial.

8

[Influence of job-related factors on the clinical course of chronic hepatitis].

Tabaru A, Matsuoka H, Maekawa S, Shimada M, Narita R, Abe S, Yamasaki M, Tashiro M, Taguchi M, Yamamoto M, Kihara Y, Kume K, Yoshikawa I, Nakamura H, Otsuki M. Tabaru A, et al. Among authors: abe s. Nihon Shokakibyo Gakkai Zasshi. 2007 Aug;104(8):1192-203. Nihon Shokakibyo Gakkai Zasshi. 2007. PMID: 17675821 Japanese.

9

Impact of steatosis on insulin secretion in chronic hepatitis C patients.

Narita R, Abe S, Tabaru A, Otsuki M. Narita R, et al. Among authors: abe s. Am J Gastroenterol. 2007 Oct;102(10):2173-80. doi: 10.1111/j.1572-0241.2007.01443.x. Epub 2006 Aug 4. Am J Gastroenterol. 2007. PMID: 17680843

10

Increased soluble IL-2 receptor levels during interferon and ribavirin treatment are associated with a good response in genotype 2a/2b patients with chronic hepatitis C.

Abe S, Narita R, Matsuhashi T, Oto T, Tabaru A, Otsuki M. Abe S, et al. Eur J Gastroenterol Hepatol. 2008 May;20(5):373-8. doi: 10.1097/MEG.0b013e3282f43aae. Eur J Gastroenterol Hepatol. 2008. PMID: 18403937

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,200 results

Search Page

Filters